Prana reports Phase IIa data for PBT2 in Huntington's

Prana Biotechnology Ltd. (ASX:PBT; NASDAQ:PRAN) reported data on Tuesday from the Phase IIa Reach2HD trial evaluating PBT2 to treat Huntington's disease (HD). Prana said 100 and 250 mg doses of oral once-daily PBT2 for 26 weeks met the primary safety endpoint and were well tolerated. On the primary efficacy endpoint of cognition, PBT2 did not significantly improve main composite score vs. placebo, though Prana said high-dose PBT2 did improve executive function composite score significantly from baseline at week 12 (p=0.005) and non-significantly from baseline at week 26 (p=0.069) vs. placebo. Neither dose of PBT2 led to significant improvements in other individual cognitive tests or in motor, functional, behavioral or global assessments over the 26-week period vs. placebo. The double-blind, U.S. and Australian trial enrolled 109 patients with early to mid-stage HD.

Prana said it plans to start a Phase III trial with PBT2 to treat HD, but declined to disclose details. Next month, the company expects to report data from the Phase II IMAGINE trial evaluating the metal protein-attenuating compound (MPAC) to treat Alzheimer's disease. ...